Intellectual Property & Patents

Salipro Biotech Obtains Patents in US and China for Direct Extraction of Membrane Proteins and Library Generation

September 09, 2022

Salipro has been granted patents in the United States and China for its proprietary technology to enable the development of therapeutics against challenging drug targets.

What Impact Will the New Unitary Patent System Have in Europe

September 02, 2022

A new unitary patent system is due to come into effect in Europe later on this year.

Merck Digital Sciences Studio Supports Early-Stage Startups

July 13, 2022

Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.

Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA

July 13, 2022

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

USPTO Issues Malaria Vaccine Patent to GeoVax

April 27, 2022

GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.

Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH

April 11, 2022

Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.

Evonetix Receives Patent for Thermally-Controlled DNA Synthesis Technology

April 08, 2022

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

ATMPS Ltd Wins US Patent for the Use of Blockchain in Advanced Medicinal Therapy Products

April 06, 2022

ATMPS Ltd has been granted a patent from the United States Patent and Trademark Office for the use of its Hataali blockchain technology used in personalized medicines.

European Patent Office Grants Further Patent to Salipro Biotech

February 10, 2022

The European Patent Office has granted another patent to Salipro Biotech, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

Immutep Granted a Chinese Patent for LAG-3 Antagonist Antibody

September 02, 2021

Immutep was granted a Chinese patent for LAG525, a LAG-3 antagonist antibody, under evaluation for cancer treatment.